![]() |
|
|
Vol. 300, Issue 2, 668-672, February 2002
Department of Pharmacology, Nihon University School of Dentistry at Matsudo, Matsudo, Japan
| |
Abstract |
|---|
|
|
|---|
The effect of tenidap [(±)-5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide], a new anti-inflammatory agent, was investigated on DNA synthesis by means of [3H]thymidine incorporation, collagen synthesis by means of [3H]proline incorporation, cell proliferation, and intracellular pH in nicardipine-reactive human gingival fibroblasts. Tenidap significantly inhibited [3H]thymidine incorporation at concentrations greater than 20 µM on the 4th and 8th day of treatment. Tenidap also significantly inhibited [3H]proline incorporation at a concentration greater than 50 µM on the 4th day and at more than 20 µM on the 8th day of treatment. The presence of 1 µM nifedipine or 1 µM nicardipine did not alter the depressing effect of tenidap. Tenidap (20 µM) also lowered intracellular pH. These results suggest that tenidap might be effective for the prevention of gingival overgrowth caused by calcium channel blockers.
| |
Introduction |
|---|
|
|
|---|
Tenidap,
(±)-5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide,
is a new anti-inflammatory agent, which has been shown to inhibit
IgE-mediated N-acetylglucosaminidase secretion from mast
cells (Conklyn et al., 1990
), release activated collagenase from
neutrophils (Blackburn et al., 1991b
), inhibit leukotriene B4 and
prostanoid syntheses in human neutrophils (Morianen et al., 1988), form
5-lipoxygenase products in human subject (Blackburn et al., 1991a
),
inhibit production of interleukin-1, -6, and tumor necrosis factor from
human Hep3B hepatoma cells (Sipe et al., 1992
), and inhibit the
antigen-induced increase in intracellular Ca2+
and also both antigen- and thapsigargin-induced
Ca2+ influx across the plasma membrane in a mast
cell line (Cleveland et al., 1993
) and in human gingival fibroblasts
(Fujii et al., 1995a
).
During the course of the study investigating the mechanism of gingival
overgrowth by nifedipine, one of the dihydropyridine calcium channel
blockers, we demonstrated that the fibroblasts derived from nifedipine
responders (reactive patients) gave trends of better cell proliferation
rate, DNA synthesis, and collagen synthesis than those from nifedipine
nonresponders (nonreactive patients) in the presence of 1 µM
nifedipine (Fujii et al., 1994
). In our previous report (Fujii et al.,
1995b
), we also found that gingival fibroblasts derived from nifedipine
nonresponder showed a greater cytosolic calcium response to bradykinin
(BK), thrombin, prostaglandins E2 and
F2
, and platelet-derived growth factor BB than
those derived from nifedipine responder. On the contrary, those derived
from nifedipine responder responded more intensively to histamine and bombesin.
The cell proliferation in cultured fibroblasts involves a sequence of
biochemical events. Among the earliest of these events are dramatic
increases in intracellular free Ca2+
concentration ([Ca2+]i)
(Byron et al., 1992
; Berridge, 1993
). BK is one of the agonists increasing [Ca2+]i
response via B2 BK receptor in gingival fibroblasts (Lerner et al.,
1992
; Fujii et al., 1995b
).
Since Ca2+ is critical for cell proliferation, it
is quite interesting to investigate the depressive effect of tenidap,
which might prevent Ca2+ influx through plasma
membrane (Cleveland et al., 1993
; Fujii et al., 1995a
) and decrease
[Ca2+]i of gingival
fibroblasts, resulting in the prevention of gingival overgrowth
initiated by drug treatment such as phenytoin, cyclosporin A, and
calcium channel blockers. Thus, the present investigation was
undertaken to clarify the effect of tenidap on gingival fibroblasts in
respect to DNA synthesis, collagen synthesis, and cell proliferation.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals and Reagents. Tenidap was kindly provided by Pfizer Pharmaceutical Co. Ltd., Tokyo, Japan. [3H]Thymidine and [3H]proline were purchased from Amersham Life Science, Tokyo, Japan. Scintillator (Ultima Gold) was purchased from Packard Japan K. K. (Tokyo, Japan). All the chemicals and reagents for tissue culture were purchased from Invitrogen Laboratories, Carlsbad, CA. BCECF-AM was purchased from Dojindo Laboratories, Kumamoto, Japan.
Cells.
Cultures of fibroblast-like cells were established
from the noninflamed gingival specimen of a male patient, 75 years old, who had been receiving nicardipine and developed gingival overgrowth during clearance of his remaining teeth. The plan to use gingival samples was accepted by the Committee of Studies involving Human Beings
of Nihon University School of Dentistry at Matsudo. Fibroblasts were
obtained by trypsinization of the primary outgrowth of the cells by the
procedure described by Fujii et al. (1994
, 1995a
). Briefly, the cells
were incubated in an atmosphere of 5% CO2/95% air at 37°C in the medium, DMEM-10 supplemented with 10% fetal calf
serum (FCS), 100 µg/ml streptomycin, 100 U/ml penicillin G, and 0.2 µg/ml amphotericin B, and routinely passaged using 0.25% trypsin and
0.02% EDTA in Dulbecco's phosphate-buffered saline (DPBS).
Homogeneity of fibroblasts was determined by flow cytometry (FACS
Vantage; Nippon Becton Dickinson Co. Ltd., Tokyo, Japan). The
fibroblasts used for experiments proliferated in the logarithmic phase
between the fifth and the eighth passage.
DNA, Collagen Syntheses, and Cell Proliferation.
Measurement
of DNA, collagen syntheses, and cell proliferation was performed in the
same manner as reported previously (Fujii et al., 1994
) with a slight
modification. Briefly, for DNA synthesis assay, fibroblasts
(approximately 6 × 103 cells) in 100 µl
of DMEM-10 were allowed to settle in a 96-well multiwell plate for
24 h. The adherent cells were washed, the medium was replaced with
DMEM-1 (the same as DMEM-10, except DMEM-1 contains 1% FCS), and then
4 µl of different concentrations of tenidap was added to make the
final concentration of 0, 1, 5, 10, 20, 50, and 100 µM and kept for
48 h. The medium was changed again with DMEM-1, and tenidap was
added in the same manner as above. The medium was also supplemented
with nifedipine (for a final concentration of 1 µM) and nicardipine
(for a final concentration of 1 µM).
[3H]Thymidine (22.2 kBq) was added to each well
on the 4th and 8th day 24 h after the last medium change and then
incorporated into the cell for 24 h. During this pulse-label
period, cells were in the S-phase stage, and proliferation was very low
because the medium (DMEM-1) contained only 1% FCS. Cells were removed
from the microplate using cell harvester, Micro Mate 196 (Packard Japan K. K.), after treatment with 0.25% trypsin and 0.02% EDTA in
DPBS. The radioactivity of incorporated
[3H]thymidine was counted using a Matrix TM 96 Direct Beta Counter (Packard Japan K. K.). A group without the
addition of calcium channel blockers served as the control. The data
are expressed as relative [3H]thymidine
incorporation rate (1-100 µM tenidap/0 µM tenidap).
| |
Results |
|---|
|
|
|---|
Homogeneity of Fibroblasts. The cell strain used in the present experiment was subjected to flow cytometry to find its homogeneity in the appearance on SC-F (difference of size and characteristics of cell surface) and SC-S (difference of inner substance).
Effect of Tenidap on DNA Synthesis.
Relative
[3H]thymidine incorporation rate is summarized
in Fig. 1. Relative
[3H]thymidine incorporation rate was calculated
by dividing the incorporated radioactivity of experimental by the
incorporated radioactivity of 0 µM tenidap. Tenidap significantly
inhibited [3H]thymidine incorporation at
concentrations of greater than 20 µM in the absence of calcium
channel blockers (control, tenidap only) and the presence of
nicardipine on both the 4th and 8th day of treatment (Fig. 1, A and B).
|
Effect of Tenidap on Collagen Synthesis.
Relative
[3H]proline incorporation rate is summarized in
Fig. 2. Relative
[3H]proline incorporation rate was calculated
by dividing the incorporated radioactivity of experimental by the
incorporated radioactivity of 0 µM tenidap. Tenidap significantly
inhibited [3H]proline incorporation at
concentrations of greater than 50 µM in the absence of calcium
channel blockers (control, tenidap only) and the presence of nifedipine
and greater than 100 µM in the presence of nicardipine on the 4th day
(Fig. 2A), and also inhibited it at concentrations of greater than 10 µM in the presence of nifedipine and greater than 20 µM in the
absence of calcium channel blockers (control, tenidap only) and the
presence of nifedipine on the 8th day (Fig. 2B).
|
Effect of Tenidap on Cell Proliferation.
Relative cell
proliferation rate is summarized in Fig.
3. Relative cell proliferation rate was
calculated by dividing the cell count of experimental by the cell count
of 0 µM tenidap. Tenidap did not show a significant difference
between 0 µM tenidap and 1 to 100 µM tenidap; however, 100 µM
tenidap significantly inhibited cell proliferation compared with 5, 10, and 20 µM tenidap in the absence of calcium channel blockers
(control, tenidap only) on the 8th day of treatment (Fig. 3B).
|
Effect of Tenidap on Intracellular pH.
The time course of
pHi after the tenidap treatment is shown in Fig.
4. Tenidap (20 µM) lowered
pHi by 0.12 unit during the measurement, 5 min.
The presence of nifedipine or nicardipine did not alter the
pHi change by tenidap (data not shown).
|
| |
Discussion |
|---|
|
|
|---|
We have previously reported that the connective tissue showed
larger bundles of dense collagenous fibers with a moderate increase of
fibroblasts in gingival overgrowth caused by nifedipine medication (Akimoto et al., 1991
). There are also many reports describing the
enhancement of collagenous fibers and number of fibroblasts in the loci
of gingival overgrowth (Ramon et al., 1984
; Lucas et al., 1985
; Nagata
et al., 1985
; Barak et al., 1987
; Tagawa et al., 1989
; Seymour, 1991
;
Fujii et al., 1994
). Therefore, the reductions of collagen formation
and fibroblast cell proliferation might play an important role in
preventing gingival overgrowth.
Our previous study indicated that the fibroblasts from patients
reactive to nifedipine and nicardipine medications gave better cell
proliferation rates, DNA synthesis and collagen synthesis with
nifedipine or nicardipine treatment compared with non-drug-treated control (Matsumoto et al., 2001
). In the present study, the fibroblasts that were confirmed to enhance cell proliferation rate, DNA synthesis, and collagen synthesis due to nifedipine or nicardipine treatment were
treated with tenidap and compared with the cells without tenidap
treatment (0 µM tenidap). Consequently, the present in vitro data
suggest that tenidap significantly inhibits DNA and collagen syntheses
at a concentration of greater than 20 µM (6.85 µg/ml). In the first
phase of the clinical trial, although plasma Cmax was 8.305, 17.006, and 21.009 µg/ml after a single oral dose of 40, 80, and 120 mg tenidap,
respectively (Pfizer Pharmaceutical Co. Ltd., unpublished data), more
than 99% of tenidap bound to plasma protein. Cleveland et al. (1993)
also indicated that the plasma drug level at therapeutic doses in
arthritis patients reaches 60 µM (20.6 µg/ml), but tenidap is
substantially bound by serum albumin. The distribution of tenidap to
oral tissue is hardly available. In the case of rats, the distribution
to salivary gland is 17.4 to 19.7% (unpublished data, Pfizer
Pharmaceutical Co. Ltd.). Thus, it could be estimated that
enough tenidap concentration might not be able to reach to the oral
tissue, which is enough to reduce DNA and collagen syntheses in
gingiva by a systemic tenidap administration. In our preliminary
experiment using rats (Matsumoto et al., 1995
), the local application
of a high dose of tenidap might be effective to prevent gingival
overgrowth caused by calcium channel blockers, especially nifedipine.
Therefore, tenidap may be one of the drugs that prevent gingival overgrowth.
Since the cells were established from the gingiva of nicardipine-reactive patients, it was thought that nicardipine and nifedipine might alter the depressive effect of tenidap. However, the presence of 1 µM nifedipine or nicardipine did not alter the depressive effect of tenidap. This fact indicates that tenidap can be locally applied during the administration of nicardipine or nifedipine to depress gingival overgrowth. Thus, one can continue systemic calcium channel blocker medication along with local application of tenidap, without gingival overgrowth.
Ives and Daniel (1987)
demonstrated that bradykinin and ionomycin
caused rapid acidification along with rapid increase of intracellular
Ca2+. Tenidap has been reported to reduce
pHi in mouse L cells (McNiff et al., 1994
, 1995
).
We have also demonstrated here that 20 µM tenidap decreased
pHi by 0.12 pH unit. Boyle et al. (1997)
reported the clamping intracellular pH 6.75 did not induce a
significant level of apoptosis of C3H-10T1/2 cells, which pH 6.0 did
induce in these cells. Thus, the continuous retention of tenidap in
local areas, such as in periodontal pockets, might affect gingival
fibroblasts to reduce its growth through apoptosis.
We have previously reported that tenidap discharges intracellular
Ca2+ store, resulting in a depletion of
intracellular Ca2+ store and that tenidap
functions on inhibition of Ca2+ influx in
gingival fibroblasts (Fujii et al., 1995a
). Thapsigargin, one of the
compounds that accelerates cell proliferation, also depletes
intracellular Ca2+ store, however, it does
accelerate Ca2+ influx through plasma membrane
(Takemura et al., 1989
; Putney, 1990
; Putney and Bird, 1993
). This
indicates that the nature of tenidap, which inhibits
Ca2+ influx through plasma membrane, plays a
quite important role for depression of gingival overgrowth.
| |
Footnotes |
|---|
Accepted for publication October 19, 2001.
Received for publication June 14, 2001.
This work was supported in part by Grants-in-Aid for Scientific Research Fund 09671908, 1997-1998 (A.F.) and 10557173, 1998-1999 (A.F.), and for Encouragement of Young Scientists 07771715, 1995 (H.M.), from the Ministry of Education, Science and Culture, Japan.
Address correspondence to: Dr. Akira Fujii, Department of Pharmacology, Nihon University School of Dentistry at Matsudo, 2-870-1 Sakaecho-Nishi, Matsudo, Chiba 271-8587, Japan. E-mail: afujii{at}mascat.nihon-u.ac.jp
| |
Abbreviations |
|---|
BK, bradykinin; [Ca2+]i, intracellular free Ca2+ concentration; DMEM-10, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; DPBS, Dulbecco's phosphate-buffered saline; pHi, intracellular pH; BCECF-AM, 3'-O-acetyl-2',7'-bis(carboxyethyl)-4- or 5-carboxyfluorescein, diacetoxymethyl ester; BCECF, 2',7'-Bis(carboxyethyl)-4- or 5-carboxyfluorescein, diacetoxymethyl ester.
| |
References |
|---|
|
|
|---|
a preliminary report.
Int J Cardiol
5:
195-204[CrossRef][Medline].This article has been cited by other articles:
![]() |
S. Parry, J. Zhang, H. Koi, F. Arechavaleta-Velasco, and M. A. Elovitz Transcytosis of Human immunodeficiency virus 1 across the placenta is enhanced by treatment with tumour necrosis factor alpha. J. Gen. Virol., August 1, 2006; 87(Pt 8): 2269 - 2278. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||